Biotechnology Value Fund

Biotechnology Value Fund

Biotechnology Value Fund

Suggest edits
Follow us
Also headquartered in San Francisco
Terms of Service Privacy Policy Cookie Statement API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2021
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

News

Investments 13

Portfolio

Portfolio Tracker

Add info
Add round
22 Jul 2020
Olema Pharmaceuticals
Olema Pharmaceuticals
$54,000,000
Venture capital (Series B)
Foresite Capital, RA Capital Management, Wellington Management, +6

Olema Oncology Secures $54 Million To Advance Lead Program In Breast Cancer

Pulse 2.0
+1
11 Jun 2020
Autobahn Therapeutics
Autobahn Therapeutics
$76,000,000
Venture capital (Series B)
ARCH Venture Partners, Invus, Biotechnology Value Fund, +7

Autobahn Therapeutics Raises $76 Million To Develop Therapies For CNS Disorders

Pulse 2.0
12 Mar 2020
Kymera Therapeutics
Kymera Therapeutics
$102,000,000
Venture capital (Series C)
Redmile Group, BlackRock, Wellington Management, +4

Kymera Therapeutics Raises $102M in Series C Financing

FinSMEs
15 May 2019
Phathom Pharmaceuticals
Phathom Pharmaceuticals
$90,000,000
Venture capital
Greenspring Associates, RA Capital Management, Frazier Healthcare Partners, +6
30 Apr 2019
Vividion Therapeutics
Vividion Therapeutics
$82,000,000
Venture capital (Series B)
Cardinal Partners, Celgene, Versant Ventures, +7
20 Dec 2018
Relay Therapeutics
Relay Therapeutics
$400,000,000
Venture capital (Series C)
Foresite Capital, Alexandria Venture, Perceptive Advisors, +7
21 May 2018
Rain Therapeutics
Rain Therapeutics
$18,400,000
Venture capital (Series A)
Perceptive Advisors, Biotechnology Value Fund, UniServices Limited’s Investors Fund

Rain Therapeutics scores $18 million Series A round for lung cancer drug

MedCity News
14 Dec 2017
Relay Therapeutics
Relay Therapeutics
$63,000,000
Venture capital (Series B)
Alexandria Venture, EcoR1 Capital, Third Rock Ventures, +4
22 Sep 2017
Realm Therapeutics, Inc.
Realm Therapeutics, Inc.
$26,000,000
Post-IPO equity
RA Capital Management, Abingworth, OrbiMed, +2
16 Aug 2017
Molecular Templates
Molecular Templates
$60,000,000
Post-IPO equity
Perceptive Advisors, Longitude Capital, Takeda Pharmaceutical, +2

https://www.bizjournals.com/austin/news/2017/08/16/austin-biotech-company-lands-on-nasdaq-with-fresh.html?ana=twt

bizjournals
+1
06 May 2016
ViewPoint Therapeutics
ViewPoint Therapeutics
$4,000,000
Venture capital (Series A)
Asset Management Ventures (AMV), Mission Bay Capital, Biotechnology Value Fund, +3

ViewPoint Therapeutics Closes $4M Series A Financing

FinSMEs
07 Jan 2014
Blueprint Medicines
Blueprint Medicines
$25,000,000
Venture capital (Series B)
Fidelity Biosciences, Third Rock Ventures, Casdin Capital, +2
03 Sep 2013
Evotec
Evotec
$40,000,000
Venture capital
Biotechnology Value Fund